TY - JOUR
T1 - Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations
AU - Deng, Kai
AU - Pertea, Mihaela
AU - Rongvaux, Anthony
AU - Wang, Leyao
AU - Durand, Christine M.
AU - Ghiaur, Gabriel
AU - Lai, Jun
AU - McHugh, Holly L.
AU - Hao, Haiping
AU - Zhang, Hao
AU - Margolick, Joseph B.
AU - Gurer, Cagan
AU - Murphy, Andrew J.
AU - Valenzuela, David M.
AU - Yancopoulos, George D.
AU - Deeks, Steven G.
AU - Strowig, Till
AU - Kumar, Priti
AU - Siliciano, Janet D.
AU - Salzberg, Steven L.
AU - Flavell, Richard A.
AU - Shan, Liang
AU - Siliciano, Robert F.
N1 - Funding Information:
Acknowledgements We thank all study participants. We thank J. Blankson for critical advice to the project; L. Alston and R. Hoh for coordinating patient recruitment; J. Alderman, C. Weibel and E. Henchey for technical assistance in the animal study. We thankthe National Institutes of Health (NIH) AIDSReagent Program for providing HIV-1 consensus B peptides. R.F.S. is supported by the Howard Hughes Medical Institute, by the Martin Delaney CARE and DARE Collaboratories (NIH grants AI096113 and 1U19AI096109), by an ARCHE Collaborative Research Grant from the Foundation for AIDS Research (amFAR 108165-50-RGRL), by the Johns Hopkins Center for AIDS Research (P30AI094189), and by NIH grant 43222. L.S. is supported by NIH grant T32 AI07019. R.A.F. is supported by the Bill and Melinda Gates Foundation and the Howard Hughes Medical Institute.
Publisher Copyright:
© 2015 Macmillan Publishers Limited.
PY - 2015/1/15
Y1 - 2015/1/15
N2 - Despite antiretroviral therapy (ART),humanimmunodeficiency virus (HIV)-1 persists in a stable latent reservoir1,2, primarily in resting memory CD41 T cells3,4. This reservoir presents a major barrier to the cure of HIV-1 infection. To purge the reservoir, pharmacological reactivation of latent HIV-1 has been proposed5 and tested both in vitro and in vivo6-8. A key remaining question is whether virusspecific immune mechanisms, including cytotoxic T lymphocytes (CTLs), can clear infected cells in ART-treated patients after latency is reversed. Here we show that there is a striking all or none pattern for CTL escape mutations in HIV-1 Gag epitopes. Unless ART is started early, the vast majority (.98%) of latent viruses carry CTL escapemutations that render infectedcells insensitive toCTLsdirected at common epitopes. To solve this problem, we identified CTLs that could recognize epitopes fromlatent HIV-1 that were unmutated in every chronically infected patient tested. Upon stimulation, these CTLs eliminated target cells infected with autologous virus derived fromthe latent reservoir, bothinvitro andinpatient-derived humanized mice. The predominance of CTL-resistant viruses in the latent reservoir poses a major challenge to viral eradication. Our results demonstrate that chronically infected patients retain a broad-spectrum viral-specific CTL response and that appropriate boosting of this response may be required for the elimination of the latent reservoir.
AB - Despite antiretroviral therapy (ART),humanimmunodeficiency virus (HIV)-1 persists in a stable latent reservoir1,2, primarily in resting memory CD41 T cells3,4. This reservoir presents a major barrier to the cure of HIV-1 infection. To purge the reservoir, pharmacological reactivation of latent HIV-1 has been proposed5 and tested both in vitro and in vivo6-8. A key remaining question is whether virusspecific immune mechanisms, including cytotoxic T lymphocytes (CTLs), can clear infected cells in ART-treated patients after latency is reversed. Here we show that there is a striking all or none pattern for CTL escape mutations in HIV-1 Gag epitopes. Unless ART is started early, the vast majority (.98%) of latent viruses carry CTL escapemutations that render infectedcells insensitive toCTLsdirected at common epitopes. To solve this problem, we identified CTLs that could recognize epitopes fromlatent HIV-1 that were unmutated in every chronically infected patient tested. Upon stimulation, these CTLs eliminated target cells infected with autologous virus derived fromthe latent reservoir, bothinvitro andinpatient-derived humanized mice. The predominance of CTL-resistant viruses in the latent reservoir poses a major challenge to viral eradication. Our results demonstrate that chronically infected patients retain a broad-spectrum viral-specific CTL response and that appropriate boosting of this response may be required for the elimination of the latent reservoir.
UR - http://www.scopus.com/inward/record.url?scp=84922764937&partnerID=8YFLogxK
U2 - 10.1038/nature14053
DO - 10.1038/nature14053
M3 - Article
C2 - 25561180
AN - SCOPUS:84922764937
SN - 0028-0836
VL - 517
SP - 381
EP - 385
JO - Nature
JF - Nature
IS - 7534
ER -